| Biotransformation of a potent anabolic steroid, mibolerone, with Cunninghamella blakesleeana, C. echinulata, and Macrophomina phaseolina, and biological … M Siddiqui, MS Ahmad, A Wahab, S Yousuf, N Fatima, N Naveed Shaikh, ... PLoS One 12 (2), e0171476, 2017 | 26 | 2017 |
| Bio-catalytic structural transformation of anti-cancer steroid, drostanolone enanthate with Cephalosporium aphidicola and Fusarium lini, and cytotoxic potential evaluation of … MI Choudhary, M Siddiqui, S Yousuf, N Fatima, MS Ahmad, H Choudhry Frontiers in Pharmacology 8, 317607, 2017 | 20 | 2017 |
| Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment Y Shen, K Crassini, S Sandhu, N Fatima, RI Christopherson, SP Mulligan, ... Leukemia & Lymphoma, 2019 | 7 | 2019 |
| Toxicological assessment of Opuntia dillenii (Ker Gawl.) Haw. cladode methanol extract, fractions and its alpha pyrones: Opuntiol and opuntioside F Siddiqui, AD Farooq, N Kabir, N Fatima, L Abidi, S Faizi Journal of ethnopharmacology 280, 114409, 2021 | 6 | 2021 |
| IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment Y Shen, K Crassini, N Fatima, M O’Dwyer, M O’Neill, RI Christopherson, ... Blood advances 4 (20), 5093-5106, 2020 | 6 | 2020 |
| The ClpP activator ONC‐212 (TR‐31) inhibits BCL2 and B‐cell receptor signaling in CLL N Fatima, Y Shen, K Crassini, EJ Iwanowicz, H Lang, DS Karanewsky, ... eJHaem, 2021 | 4 | 2021 |
| Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment Y Shen, KR Crassini, N Fatima, R Christopherson, SP Mulligan, OG Best Blood 134, 5443, 2019 | 4 | 2019 |
| Adenylated proteins in mouse B16-F10 melanoma cells cluster in functional categories: a new paradigm for cellular regulation? N Fatima, M Alomari, L Belov, Y Shen, RI Christopherson Nucleosides, Nucleotides & Nucleic Acids 41 (3), 255-263, 2022 | 2 | 2022 |
| Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia N Fatima, KR Crassini, L Thurgood, Y Shen, RI Christopherson, B Kuss, ... Cancer Drug Resistance 3 (3), 532, 2020 | 2 | 2020 |
| The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro N Fatima, Y Shen, K Crassini, O Burling, L Thurgood, EJ Iwanowicz, ... Leukemia & Lymphoma, 1-13, 2024 | | 2024 |
| The effect of HYPE knock-out on the AMPylome of human OSU-CLL leukemia cells N Fatima, OG Best, L Belov, RI Christopherson Leukemia & Lymphoma 65 (2), 242-249, 2024 | | 2024 |
| Targeting the integrated stress response (ISR) as a therapeutic option for chronic lymphocytic leukemia N FATIMA RIZWAN | | 2021 |
| The dual PI3/PIM-kinase inhibitor, IBL-202, is synergistic with venetoclax against TP53-deficient CLL cells under conditions that mimic the lymph node microenvironment Y Shen, K Crassini, N Fatima, M O'Dwyer, M O'Neill, R Christopherson, ... LEUKEMIA & LYMPHOMA 61, 69-70, 2020 | | 2020 |
| The integrated stress response (ISR) inhibitor, TR57, is synergistic with venetoclax in CLL irrespective of TP53 status N Fatima, K Crassini, Y Shen, R Christopherson, EJ Iwanowicz, ... LEUKEMIA & LYMPHOMA 61, 71-72, 2020 | | 2020 |
| TR57, an Inhibitor of the Integrated Stress Response, Is Synergistic with Venetoclax Against CLL Cells, Independent of Their TP53 Status N Fatima, Y Shen, KR Crassini, E Iwanowicz, R Christopherson, G Best, ... Blood 134, 1735, 2019 | | 2019 |
| ONC-212 (I-39), a Novel Inhibitor of the UPR, Is Cytotoxic and Cytostatic Against CLL Cells Under in Vitro Conditions That Mimic the Tumor Microenvironment N Rizwan, Y Shen, E Iwanowicz, SP Mulligan, KR Crassini, ... Blood 132, 3145, 2018 | | 2018 |
| TRANSLATIONAL INHIBITORS INDUCES APOPTOSIS IN PROSTATE AND COLORECTAL CANCER CELL LINES N Fatima, H MW | | |
Richard Ian ChristophersonEmeritus Professor, University of SydneyVerified email at sydney.edu.au
